The glucagon-like peptide-1 analog liraglutide suppresses ghrelin and controls diabetes in a patient with Prader-Willi syndrome
Prader-Willi syndrome (PWS) is a genetic disease characterized by severe morbid obesity in association with hyperphagia and type 2 diabetes mellitus. Liraglutide is a glucagon-like peptide (GLP)-1 analog that controls appetite, decreases body weight and improves glycemic control. However, it is uncl...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | 英語 |
| 出版事項: |
2012
|
| オンライン･アクセス: | https://doi.org/10.1507/endocrj.ej12-0074 https://www.jstage.jst.go.jp/article/endocrj/59/10/59_EJ12-0074/_pdf |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|